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ABSTRACT
The occurrence of three cases of meningococcal
disease among children in a small community, two
of whom attended the same day-care centre,
prompted a programme of mass antibiotic pro-
phylaxis. Nasopharyngeal and throat swabs were
obtained on three occasions from all children
registered at the day-care centre. Serogroup B
Neisseria meningitidis was isolated from 13 of 61
children before prophylaxis, from three children
after 2 weeks, and from 19 children after 3 months.
Repetitive extragenic palindromic PCR analysis
identified several meningococcal strains before
treatment, one of which became predominant after
3 months. Mass antibiotic prophylaxis initially
suppressed meningococcal carriage, but the
carriage rate subsequently rebounded.
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Neisseria meningitidis is a major cause of bacterial
meningitis. Asymptomatic nasopharyngeal colo-
nisation with N. meningitidis occurs in 5–10% of
adults. Molecular subtyping of meningococci can
be used to demonstrate epidemiological links
among patients and carriers, and to monitor the
changing epidemiology of the disease. Repetitive
extragenic palindromic sequence-based PCR
(REP-PCR) has been used successfully to type
various bacteria [1–7], including meningococci
[8–10]. The aim of the present study was to use
REP-PCR to investigate an outbreak of meningo-
coccal disease in a small community in order to
examine the appropriateness of the control meas-
ures applied.
Four children, including three from Netzarim, a
small community of 370 inhabitants in Israel,
were diagnosed with meningococcal meningitis.
Two patients (the first and last cases) were
diagnosed following isolation of N. meningitidis
serogroup B, and the other two cases were
diagnosed clinically. Case definition was based
on the immediate needs of the decision-making
process in the course of the event, and included
high fever, meningitis and ⁄ or petechial rash
during the specified period in Netzarim.
Patient 1, a girl aged 4 years, was diagnosed a
week before patient 2, a girl aged 12 years, with
clinical signs and symptoms of meningococcae-
mia (this patient received ceftriaxone on the way
to hospital). Patient 3, the brother (aged 1.5 years)
of patient 2, developed high fever and upper
respiratory tract symptoms while receiving pro-
phylaxis. Gram-negative cocci were grown from
cerebrospinal fluid culture without final identifi-
cation. Patients 1 and 3 attended the same day-
care centre in Netzarim. Patient 4, a boy aged
17 years from Jerusalem with clinical signs of
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meningitis, was added to this cluster because of a
visit from a girl whose sister was attending the
same day-care centre in Netzarim.
All children registered at the day-care centre
were screened for meningococcal carriage using
nasopharyngeal and throat swabs transported in
Amies medium (Medical Wire & Equipment Co.
Ltd, Corsham, Wiltshire, UK), and all received
chemoprophylaxis with rifampicin (10 mg ⁄ kg
body weight, twice-daily for 2 days). The appear-
ance of the fourth case within a 2-week period
prompted the initiation of mass prophylaxis with
the above dose schedule for all children, and with
600 mg of rifampicin twice-daily for the adult
residents of Netzarim. Administration of chemo-
prophylaxis to all residents required 2–3 days.
Compliance was complete. Nasopharyngeal and
throat carriage of meningococci were assessed
2 weeks and 3 months following the antibiotic
prophylaxis. No additional prophylaxis was given.
The swabs were plated on Tryptic Soy Agar
plates supplemented with sheep blood 5% v ⁄ v
and vancomycin 4 mg ⁄L (HyLabs, Rehovot,
Israel). Routine colonial morphology and acid
production tests [11] were performed to identify
N. meningitidis, and the resulting isolates were
serotyped. Susceptibility tests were performed for
the laboratory-confirmed cases using Etests (AB
Biodisk, Solna, Sweden) according to the manu-
facturer’s instructions.
Genomic DNA was prepared from each isolate
using a DNeasy tissue kit (Qiagen, Valencia, CA,
USA). PCRs were performed using a single 22-base
primer BOXA1R (MWG Biotech, High Point, NC,
USA) [8], template DNA, dNTPs (MBI Fermentas,
Hanover, MD, USA), and SuperTherm DNA
polymerase (Eroline, London, UK). The PCR con-
ditions were those described by Woods et al. [8].
Cultures were positive for N. meningitidis sero-
group B before the administration of prophylactic
treatment for 13 (21.3%) of the 61 children
attending the day-care centre. Two weeks after
treatment, cultures were positive for three (4.9%)
children, one of whom was a former carrier, and
two who had previously negative cultures. After
3 months, 19 (31.1%) cultures were positive,
including those for five of the 13 children who
were positive before prophylaxis, one of the three
carriers at 2 weeks, and 13 children who were
negative according to both previous screens. All
cultures were negative for serotypes other than
group B. The isolates from the two laboratory-
confirmed cases were susceptible to rifampicin
and ceftriaxone.
Fig. 1 shows the REP-PCR profiles of isolates
from two patients and ten carriers before chem-
oprophylaxis and 2 weeks after (two isolates).
The profiles of the isolates obtained from the
carriers were different from those of the two
identical isolates obtained from the sick children.
Fig. 2 shows the REP-PCR profiles for 16 isolates
obtained 3 months after prophylaxis. Profiles that
differed from each other by less than three
fragments were arbitrarily considered to be
closely related, as recommended for the analysis
of restriction patterns produced by pulsed-field
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Fig. 1. Repetitive extragenic palindromic sequence-based
PCR profiles of the clinical isolates (lanes 1 and 2) and the
carriers before prophylaxis (lanes 3–12) and 2 weeks after
prophylaxis (lanes 13 and 14). The profiles of the isolates
from the sick children are identical and differ from the
profiles of the isolates from the carriers. The isolates in
lanes 5 and 6 share similar patterns. The isolates in lanes
10–14 belong to carriers from the period before prophy-
laxis, as well as 2 weeks afterwards, and share another
similar pattern. Mw1, 1-kb DNA ladder; Mw2, 100-bp
DNA ladder.
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Fig. 2. Repetitive extragenic palindromic sequence-based
PCR profiles of the isolates from carriers at 3 months after
prophylaxis. The profiles of isolates in lanes 15–17, 19, 21,
23, 26 and 27 are closely related and resemble those
of isolates from carriers before prophylaxis (Fig. 1, lanes
10–14). Mw1, 1-kb DNA ladder; Mw2, 100-bp DNA ladder.
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gel electrophoresis [12]. Using this interpretation,
the isolates from eight of the carriers at 3 months
(Fig. 2, lanes 15–17, 19, 21, 23, 26, 27) had profiles
that were related closely to those of the isolates
obtained from three (20%) carriers identified
before prophy1axis (Fig. 1, lanes 10–12), and to
those of the isolates from two of the three carriers
identified after 2 weeks (Fig. 1, lanes 13 and 14).
Mass prophy1axis is rare1y indicated for the
prevention of meningitis, because of concerns
regarding the emergence of resistant strains [13].
The few studies dealing with mass prophylaxis in
specific populations [14–16] have revealed, in
most cases, a suppression of carriage after mass
prophylaxis, with subsequent recurrence. The
present molecular study supports these findings:
3 months after the prophylaxis campaign, the
carriage rate rose, mainly because of recolonisa-
tion by a pre-existing strain.
The re-emergence of meningococcal colonisa-
tion occurred after a relatively short period
(2 weeks to 3 months). Other studies involving
an Arctic community [16] and military barracks
[17,18] have demonstrated similar results (after at
least 9 weeks and 8–12 weeks, respectively),
while another study from Israel showed re-emer-
gence after a period of 6–12 months [14]. Early
recolonisation in the present study may have
resulted from the crowded living conditions in
Netzarim and the limited movement in and out of
the community for security reasons.
REP-PCR uses repetitive DNA sequences as
primers, yielding specific DNA fingerprint pat-
terns [1,19]. The use of this method in the
investigation of a meningococcal outbreak has
significant advantages in that it is fast, inexpen-
sive [20], reliable and easy to perform. Above all,
the method is very sensitive at the subspecies
level. This was confirmed in the present study by
its ability to discriminate among the carriers, and
between the carriers and the sick children.
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ABSTRACT
Exiguobacterium spp. are alkaliphilic, halotolerant,
non-spore-forming Gram-positive bacilli, hitherto
uncharacterised from human infections. Six
isolates of Exiguobacterium aurantiacum were
obtained from patients with bacteraemia, three
of whom had myeloma. All isolates formed
orange–yellow pigmented colonies on blood agar,
were catalase- and DNase-positive, and grew on
nutrient agar at pH 10 and in the presence of
NaCl 6% w ⁄ v. The six isolates were susceptible to
all antimicrobial agents tested and were uniform
in their fatty acid and mass spectrum profiles.
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Coryneform bacteria include a diverse range of
bacterial genera grouped together as aerobic non-
spore-forming Gram-positive bacilli. Of these, the
genus Exiguobacterium was first isolated from
potato-processing effluent in 1983 [1] in the form
of a single species, Exiguobacterium aurantiacum.
Eight other alkaliphilic and halotolerant species
have been described subsequently, namely
Exiguobacterium acetylicum, Exiguobacterium antart-
icum, Exiguobacterium undae, Exiguobacterium oxido-
tolerans, Exiguobacterium aestuarii, Exiguobacterium
marinum, Exiguobacterium mexicanum and Exiguo-
bacterium artemiae [2,3]. A report in 2003 used 16S
rDNA sequence homology to indicate the possible
presence of E. aurantiacum in a patient with
periodontitis [4], and a novel Exiguobacterium sp.
was identified from blood culture in 2006 using
the same technology [5]. The present study
reports the identification of a further six isolates
of E. aurantiacum from blood cultures over a
10-year period. The first case was a male aged
27 years with a history of intravenous drug abuse.
The patient presented to hospital with a swollen
and tender left leg, with cellulitis of the left groin
where he had injected himself 2 days previously.
On the following day, blood samples were taken,
from which Gram-positive yellow-pigmented
colonies were isolated. Three further isolates were
from adult males, two of whom had multiple
myeloma and the third of whom had suspected
infective endocarditis. The fifth case was a neo-
nate. All of these patients responded to therapy
and the organism was not recovered from sub-
sequent specimens.
Full clinical information was available for the
sixth patient, who was a Caucasian male aged
55 years, diagnosed with IgG kappa multiple
myeloma 4 years previously. This patient
received local radiotherapy, corticosteroids and
six courses of infusional chemotherapy via an
indwelling central venous line. During the final
course of chemotherapy, the patient became
febrile (38.2C) and experienced rigors after the
indwelling central line was flushed. The patient
was otherwise well and not neutropenic, and was
therefore treated empirically with intravenous
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